Seminars in Oncology
Volume 33 , Pages 15-18 , February 2006

Clinical Experience With Pemetrexed in Breast Cancer

  • Miguel Martin

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Miguel Martin, Servicio de Oncología Médica, Hospital Universitario San Carlos, Ciudad Universitaria s/n, 28040 Madrid, Spain

References 

  1. Hortobagyi GN . Treatment of breast cancer . N Engl J Med . 1998;339:974–984
  2. Wiserman L , Spencer CM . Paclitaxel (An update of its use in the treatment of metastatic breast cancer and ovarian and other gynecological cancers) . Drugs Aging . 1998;12:305–334
  3. Van Oosterom AT , Schrivers D . Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience . Anticancer Drugs . 1995;6:356–368
  4. Hanauske AR , Chen V , Paoletti P , et al.   Pemetrexed disodium (A novel antifolate clinically active against multiple solid tumors) . Oncologist . 2001;6:363–373
  5. Shih C , Thomton DE . Preclinical pharmacology studies and development of a novel multitargeted antifolate, MTA (LY231514) . In:  Jackman AL editors. Antifolate Drugs in Cancer Therapy . Totowa, NJ: Humana Press; 1999;p. 183–201
  6. Chen VJ , Bawley JR , Gossett L , et al.   Activity of LY231514 against several enzymes in the folate-dependent pathways . Proc Am Assoc Cancer Res . 1996;37:2598; (abstr)
  7. John W , Picus J , Blanke C , et al.   Multitargeted antifolate (pemetrexed disodium), LY231514) in patients with advanced colorectal cancer. Results from a phase II study . Cancer . 2000;88:1807–1813
  8. Pivot X , Raymond E , Gedouin D , et al.   Phase II trial of MTA (multitargeted antifolate) in advanced or recurrent squamous cell carcinoma of the head and neck . Proc Am Soc Clin Oncol . 1999;18:397a; (abstr)
  9. Paz-Ares L , Tabernero J , Moyano A , et al.   Significant activity of multitargeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder (Results of a phase II trial) . Ann Oncol . 1998;9:292–297
  10. Celio L , Bajetta E , Toffolatti L , et al.   Phase II trial of pemetrexed disodium administered every 21 days in patients with gastric cancer (Efficacy and toxicity without and with folic acid) . Ann Oncol . 2000;11:65–69
  11. Niyikiza C , Walling J , Thornton D , et al.   LY231514 (MTA) (Relationship of vitamin metabolite profile to toxicity) . Proc Am Soc Clin Oncol . 1998;17:558; (abstr)
  12. Bunn P , Paoletti P , Niyikiza C , et al.   Vitamin B12 and folate reduce toxicity of Alimta (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite . Proc Am Soc Clin Oncol . 2001;20:300; (abstr)
  13. Fossella F , Obasaju C , Paul S , et al.   Pemetrexed vs docetaxel for non-small cell lung cancer (NSCLC): Could vitamin supplementation affect docetaxel survival? An exploratory analysis . Proc Am Soc Clin Oncol . 2004;23:646; (abstr 7131)
  14. Scagliotti GV , Shin DM , Kindler HL , et al.   Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma . J Clin Oncol . 2003;21:1556–1561
  15. Vogelzang NJ , Rusthoven JJ , Symanowski J , et al.   Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma . J Clin Oncol . 2003;21:2636–2644
  16. Hanna N , Shepherd FA , Fossella FV , et al.   Randomized phase III trial of pemetrexed versus docetaxel in patients with non–small-cell lung cancer previously treated with chemotherapy . J Clin Oncol . 2004;22:1589–1597
  17. Miles DW , Smith IE , Coleman RE , et al.   A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer . Eur J Cancer . 2001;37:1366–1371
  18. Martin M , Spielmann M , Namer M , et al.   Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines . Ann Oncol . 2003;14:1246–1252
  19. Spielmann M , Martin M , Namer M , et al.   Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) metastatic breast cancer patients previously treated with an anthracycline and a taxane (An interim analysis) . Clin Breast Cancer . 2001;2:47–51
  20. Llombart-Cussac A , Theodoulou M , Rowland K , et al.   A phase II trial of pemetrexed disodium (ALIMTA, LY23154) in metastatic breast cancer (MBC) patients who have failed anthracyclines (A) and taxanes (T) (salvage chemotherapy) . Breast Cancer Res Treat . 2000;64:120a; (abstr 526)
  21. Theodoulou M , Llombart A , Cruciani G , et al.   Pemetrexed disodium (Alimta, LY231514, MTA) in locally advanced or metastatic breast cancer (MBC) patients with prior anthracycline or anthracenedione and taxane treatment (Phase II study) . Proc Am Soc Clin Oncol . 2000;19:130a; (abstr 506)
  22. Mennel RG , O’Shaughnessy J , Blum JL , et al.   Pemetrexed disodium (ALIMTA, LY231514, MTA) in advanced breast cancer (ABC) patients (pts) with prior anthracycline or anthracenedione, taxane and capecitabine treatment (A phase II study) . Proc Am Soc Clin Oncol . 2001;20:49a; (abstr 194)
  23. Gomez HL , Hanauske AR , Santillana S , et al.   A phase II trial of pemetrexed in previously untreated breast cancer . Proc Am Soc Clin Oncol . 2002;21:57a; (abstr 225)
  24. Hammond LA , Forero L , Beeram M , et al.   Phase I study of pemetrexed (LY231514) with vitamin supplementation in patients with locally advanced or metastatic breast cancer . Proc Am Soc Clin Oncol . 2003;22:133; (abstr 532)

 Dr Martin has served as a consultant to Sanofi-Aventis, Bristol-Myers Squibb, Eli Lilly and Co, and Pharmamar.

PII: S0093-7754(05)00326-X

doi: 10.1053/j.seminoncol.2005.07.027

Seminars in Oncology
Volume 33 , Pages 15-18 , February 2006

Article Tools

* Image Usage & Resolution